Final FDA Guidance: Keeping the Surgical Suite from Becoming a Manufacturing Facility
By Justin M. Mann An early focus of the U.S. Food and Drug Administration (FDA) under the new leadership of FDA Commissioner Scott Gottlieb, MD, has been regenerative medicines, which “hold significant promise for transformative and potentially curative treatments for some of humanity’s most troubling and intractable maladies.” One of the areas of regenerative medicine […]
